Impact of Angiotensin Receptor Blocker Use on Overall Survival Among Patients Undergoing Resection for Pancreatic Cancer. (Q40462627)

20 September 2017

title

Impact of Angiotensin Receptor Blocker Use on Overall Survival Among Patients Undergoing Resection for Pancreatic Cancer. (English)

1 reference

20 September 2017

5

Timothy M Pawlik

1 reference

20 September 2017

Marcelo Cerullo

1

1 reference

20 September 2017

Faiz Gani

series ordinal

2

1 reference

20 September 2017

Sophia Y Chen

series ordinal

3

1 reference

20 September 2017

Joseph K Canner

series ordinal

4

1 reference

20 September 2017

publication date

20 April 2017

1 reference

20 September 2017

published in

World Journal of Surgery

1 reference

20 September 2017

volume

41

1 reference

20 September 2017

issue

9

1 reference

20 September 2017

page(s)

2361-2370

1 reference

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Angiotensin II regulates the expression of monocyte chemoattractant protein-1 in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

A local pancreatic renin-angiotensin system: endocrine and exocrine roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Effects of angiotensin II receptor antagonist, Losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Sample-size formula for the proportional-hazards regression model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Confounding control in healthcare database research: challenges and potential approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Role of pancreatic stellate cells in chemoresistance in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

The role of pancreatic stellate cells in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Limitations of administrative databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00268-017-4021-8

Identifying complications of care using administrative data.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28429090

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A note on quantifying follow-up in studies of failure time

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28429090

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28429090

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00268-017-4021-8

1 reference

Dimensions Publication ID

20 September 2017

1085026300

0 references

1 reference